Patients' and clinicians' attitudes after the Women's Health Initiative study

Menopause

Volumn 11, Issue 1, 2004, Pages 57-61

  Blümel, Juan Enrique ^a,b   Castelo Branco, Camil ^c,d   Chedraui, Peter A ^e   Binfa, Lorena ^a   Dowlani, Bravna ^a   Gómez, María Soledad ^a   Sarrá, Salvador ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL BARROS LUCO TRUDEAU   (Chile)

^c HOSPITAL CLÍNIC   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e UNIVERSIDAD CATÓLICA DE SANTIAGO DE GUAYAQUIL   (Ecuador)

Author keywords

Hormone therapy; Menopause; Women's Health Initiative

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; MEDROXYPROGESTERONE ACETATE; TIBOLONE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; PATIENT ATTITUDE; PRESCRIPTION; PUBLICATION; RESOURCE ALLOCATION; RISK BENEFIT ANALYSIS; SOCIOECONOMICS; STATISTICAL ANALYSIS; AGED; ATTITUDE TO HEALTH; CHILE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG UTILIZATION; ESTROGEN THERAPY; HEALTH PERSONNEL ATTITUDE; MALE; MIDDLE AGED; PATIENT; PHYSICIAN; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

ADULT; AGED; ATTITUDE OF HEALTH PERSONNEL; CHILE; DRUG UTILIZATION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; PATIENTS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS; SOCIOECONOMIC FACTORS;

EID: 3242658564     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GME.0000075503.60230.61     Document Type: Article

References (19)

1. Shojania KG, Mariani SM, Lundberg GD. MedGenMed's Selection of the Top 10 Medical/Health Stories of 2002. Medscape General Medicine. Available at: http://www.medscape. com/viewarticle/446310. Accessed on January 21, 2003.
2. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Post-menopausal hormone replacement therapy: scientific review. JAMA 2002;288:872-881.
3. Beral V, Banks E, Reeves G. Evidence from randomized trials on the long-term effects of hormone replacement therapy. Lancet 2002;360:942-944.
4. Tattersall MH. Risks and benefits of postmenopausal combined hormone replacement therapy. Med J Aust 2002;177:173-174.
5. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044-1049.
6. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
7. Blumel JE. Coloquio Latinoamericano. Conductas Terapéuticas después del estudio WHI. Ed Prosam. Santiago de Chile: Laser SA; 2002.
8. Lemay A. The relevance of the Women's Health Initiative results on combined hormone replacement therapy in clinical practice. J Obstet Gynaecol Can 2002;24:711-715.
9. Gass MLS, Utian WH, Ettinger B, et al. Amended report from the NAMS advisory panel on postmenopausal hormone therapy. Available at: http://www.menopause.org/news.html#advisory. Accessed on January 21, 2003.
10. Blake JM, Collins JA, Reid RL, et al. The SOGC statement on the WHI report on estrogen and progestin use in postmenopausal women. J Obstet Gynaecol Can 2002;24:783-790,793-802.
11. Blumel JE, Castelo-Branco C, Riquelme R, et al. Use of hormone replacement therapy among Chilean women: a comparison between socioeconomic levels. Menopause 2002;9:377-380.
12. Prescript. Informe Noviembre 2002. IMS Health. Santiago, Chile; 2002.
13. The Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative re-analysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-1059.
14. Salminen TM, Saarenmaa IE, Heikkila MM, Hakama M. Is a dense mammographic parenchymal pattern a contraindication to hormonal replacement therapy? Acta Oncologica 2000;39:969-972.
15. Erel CT, Esen G, Seyisoglu H, et al. Mammographic density increase in women receiving different hormone replacement regimens. Maturitas 2001;40:151-157.
16. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
17. Cano A, Van Baal WM. The mechanisms of thrombotic risk induced by hormone replacement therapy. Maturitas 2001;40:17-38.
18. Herkert O, Kuhl H, Sandow J, Busse R, Schini-Kerth VB. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation 2001;104:2826-2831.
19. Gompel A, Siromachkova M, Lombet A, Kloosterboer HJ, Rostene W. Tibolone actions on normal and breast cancer cells. Eur J Cancer 2000;36:S76-S77.